These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Reduction of coagulation factor XIII concentration in patients with myocardial infarction, cerebral infarction, and other thromboembolic disorders. Alkjaersig N; Fletcher AP; Lewis M; Ittyerah R Thromb Haemost; 1977 Dec; 38(4):863-73. PubMed ID: 579691 [TBL] [Abstract][Full Text] [Related]
6. Fibrinolytic activity in adult Kenyan patients with sickle cell disease. Aluoch JR East Afr Med J; 1998 Jun; 75(6):351-2. PubMed ID: 9803619 [TBL] [Abstract][Full Text] [Related]
7. Factor XIII in human plasma and platelets. McDonagh J; McDonagh RP; Delâge JM; Wagner RH J Clin Invest; 1969 May; 48(5):940-6. PubMed ID: 5780202 [TBL] [Abstract][Full Text] [Related]
8. [Fibrinogen and fibrin structure in patients with cirrhosis of the liver (author's transl)]. Klingemann HG; Brunswig D; Liehr H Z Gastroenterol; 1978 Sep; 16(9):564-73. PubMed ID: 706517 [TBL] [Abstract][Full Text] [Related]
9. Red cell distribution width in sickle cell disease. Webster P; Castro O Ann Clin Lab Sci; 1986; 16(4):274-7. PubMed ID: 3740796 [TBL] [Abstract][Full Text] [Related]
10. Using serial haemorheological parameters to assess clinical status in sickle cell anaemia patients in vaso-occlussive crisis. Awodu OA; Famodu AA; Ajayi OI; Enosolease ME; Olufemi OY; Olayemi E Clin Hemorheol Microcirc; 2009; 41(2):143-8. PubMed ID: 19252237 [TBL] [Abstract][Full Text] [Related]
12. Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis. Vaziri ND; Gonzales E; Barton CH; Chen HT; Nguyen Q; Arquilla M J Lab Clin Med; 1991 Feb; 117(2):152-6. PubMed ID: 1993857 [TBL] [Abstract][Full Text] [Related]
13. Erythrocyte and plasma magnesium in sickle-cell anaemia. Olukoga AO; Adewoye HO; Erasmus RT; Adedoyin MA East Afr Med J; 1990 May; 67(5):348-54. PubMed ID: 2390957 [TBL] [Abstract][Full Text] [Related]
15. "Platelet function, fibrinogen and MISFI--an immunohaematological study in sickle cell crisis". Gupta VL; Dube GK; Chaubey BS; Saoji AM J Assoc Physicians India; 1981 Mar; 29(3):183-7. PubMed ID: 7275919 [No Abstract] [Full Text] [Related]
16. Platelet activation during steady state sickle cell disease. Westwick J; Watson-Williams EJ; Krishnamurthi S; Marks G; Ellis V; Scully MF; White JM; Kakkar VV J Med; 1983; 14(1):17-36. PubMed ID: 6224876 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the fibrin stabilizing factor in human platelets: its content in normal thrombocytes and in platelets with functional defects. Wenzel E; Oppolzer R Acta Univ Carol Med Monogr; 1972; 53():173-8. PubMed ID: 4133928 [No Abstract] [Full Text] [Related]
18. [Proceedings: Determination of Factor XIII (fibrin-stabilizing factor) in plasma and blood platelets]. Ballerini G; Franceschini F; Guerra S; Meduri P; Scagliarini F Quad Sclavo Diagn; 1973 Mar; 9(1):497-581. PubMed ID: 4210088 [No Abstract] [Full Text] [Related]
19. Classification of red blood cells as normal, sickle, or other abnormal, using a single image analysis feature. Wheeless LL; Robinson RD; Lapets OP; Cox C; Rubio A; Weintraub M; Benjamin LJ Cytometry; 1994 Oct; 17(2):159-66. PubMed ID: 7835166 [TBL] [Abstract][Full Text] [Related]
20. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Koenig S; Gerstner T; Keller A; Teich M; Longin E; Dempfle CE Blood Coagul Fibrinolysis; 2008 Jul; 19(5):375-82. PubMed ID: 18600085 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]